Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS

*Division of Nephrology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada;

†Maisonneuve-Rosemont Hospital Research Center, Montreal, Quebec, Canada;

‡Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada;

§Division of Nephrology and Hypertension, University of North Carolina Kidney Center and

‖Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina;

§Division of Nephrology and Hypertension, University of North Carolina Kidney Center and

§Division of Nephrology and Hypertension, University of North Carolina Kidney Center and

‖Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina;

§Division of Nephrology and Hypertension, University of North Carolina Kidney Center and

‡Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada;

¶Division of Nephrology, Montreal Children’s Hospital, Montreal, Quebec, Canada; and

**Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

§Division of Nephrology and Hypertension, University of North Carolina Kidney Center and